Empagliflozin

That’s not quite right. Empagliflozin, an SGLT2 inhibitor, improves glycaemic control and reduces heart failure hospitalization and renal outcomes in appropriate patients, but it does not relieve exertional angina. There is no indication of diabetes or symptomatic heart failure driving his chest pain, and SGLT2 inhibitors do not reduce myocardial oxygen demand during exertion in the way that other drugs would.  

Please go back and re‑consider.  

  • Further developments

Map: Mattias Garcia_UNIC (1092)
Node: 20640
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • Low-glucose media for energy-limited systems (DMEM-LG)
  • A
  • C
  • Pelo
  • PPIs are weak acids converted by CYP450 enzymes to the active form in parietal cells
  • Ignore the emotional expression.
  • High-glucose media for fast-growing cells (DMEM)
  • B
  • ECG
  • PPIs are weak bases activated by protonation in parietal cells
  • Blame the patient for non-adherence
  • new node
  • Validate the emotion
  • Contractility
  • E
  • Heart rate
  • Afterload
  • B
  • Empagliflozin

Reminder

empty_reminder_msg

FINISH

Time is up